Cloudreach and AWS Sign Strategic Collaboration Agreement to Accelerate Global Cloud Adoption
11.8.2021 12:00:00 EEST | Business Wire | Press release
Cloudreach, a leading independent cloud services provider, and Amazon Web Services (AWS), today unveiled a new Strategic Collaboration Agreement. The wide-ranging agreement will mean an acceleration of the companies’ joint go-to-market proposition, along with investments in Cloudreach software innovation, geographical expansion and the launch of a Talent Academy.
This agreement builds on the well-established 12-year relationship between Cloudreach and AWS. Cloudreach will expand within North America and Europe including into new territories Canada, Poland, Spain and the Nordics. In addition, Cloudreach will make significant investments in software, further developing its SMART Migration™ and SMART Modernization™ services. These services are designed to accelerate enterprise cloud adoption through intelligent automation and will help more customers to realize the benefits of AWS services with far greater efficiency.
Cloudreach CEO, Brooks Borcherding, said: “After 12 years of collaboration with AWS, we’re excited to be entering this new phase of growth. Together, we’re focused on delivering the promise of the cloud through new software-driven capabilities coupled with industry-best practices and expertise. For our customers this will mean adopting AWS cloud more efficiently and with greater confidence, achieving a faster time to value.”
Launch of Cloudreach Talent Academy
A key initiative within the agreement is the launch of a Talent Academy. The Academy is designed to train hundreds of diverse and promising candidates to become the next generation of cloud professionals. For entry into the program, Cloudreach will look for candidates with a passion for building their career in cloud, even if they do not have a technical background, and fast-track their technical development.
The program will bring more talent into the AWS community, offering candidates a path to acquire and upskill their AWS capabilities. The Talent Academy is unique in its emphasis on recruiting from a diverse pool of candidates who traditionally have not selected technical career paths. Cloudreach expects hundreds of candidates to become AWS-certified and get the hands-on experience to become cloud consultants, engineers, architects, and developers.
“Cloudreach is committed to addressing underrepresentation and the lack of diversity within the technology workforce and cloud industry. This purpose-driven investment is one of the most exciting aspects of this collaboration with AWS. We’re dedicated to be helping future professionals develop their careers where they will solve complex business challenges for our joint customers,” added Borcherding.
Doug Yeum, Head of Worldwide Channels and Alliances at AWS, said: “We are delighted to build upon the 12-year relationship with AWS Premier Partner, Cloudreach. This collaboration means AWS can bring the highest level of cloud native expertise to an even wider audience with Cloudreach, significantly accelerating the pace of global cloud adoption. We are also particularly appreciative of Cloudreach’s focus on expanding the diverse talent pool of AWS-skilled professionals, which aligns with our leadership principles as a company.”
This engagement will provide AWS and Cloudreach customers with compelling new SMART Migration™ and SMART Modernization™ service offerings to dramatically accelerate cloud adoption and reduce time-to-value by 40%. These new offerings leverage both Cloudamize, a leading planning, assessment, and migration automation software, and Sunstone, a cloud modernization machine learning engine to make continuous modernization recommendations for legacy and cloud deployed services.
Marie Measures, Chief Technology Officer at Sanne Group, the alternative asset fund administrator, said: “The possibilities are endless when you engage with an AWS Partner that’s flexible, easy to work with, and shares your organization’s values. We want to move quickly along our cloud journey and, thanks to Cloudreach and AWS, we have a well-structured transformational roadmap.”
For more details about the collaboration between AWS and Cloudreach, please visit: www.cloudreach.com/en/partners/aws-premier-consulting-partner/
– ENDS –
About Cloudreach
Cloudreach is the world’s leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation. With more than 10 years of cloud native experience, we’ve built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our work, visit www.cloudreach.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005334/en/
Contact information
Press Contact
Rahim Hakimi
Email: rahim.hakimi@cloudreach.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
